Update Noonan Syndrome

[caufieldjh]

No description provided.

[claude]

Claude finished @caufieldjh's task in 6m 56s —— View job

---

PR Review: Update Noonan Syndrome

• Read the Noonan Syndrome YAML file
• Review evidence references and snippets
• Check conformance with CLAUDE.md guidelines
• Assess biological/clinical validity
• Check completeness
• Post final review

---

Summary

This is a substantial and well-executed curation of Noonan Syndrome, adding ~797 lines covering pathophysiology, phenotypes, genetics, treatments, datasets, and differential diagnoses. The entry is scientifically accurate and uses up-to-date references (heavily 2024–2026). A few issues need attention before merging.

---

Biological and Clinical Validity ✅

Strengths:

• The RAS-MAPK pathophysiology is correctly organized across six upstream drivers (SHP2/PTPN11, SOS1, RAF1, RIT1, LZTR1, MRAS) converging on ERK cascade hyperactivation
• Genotype–phenotype correlations are accurate and well-cited: PTPN11 → pulmonary stenosis (70.6%), RAF1 → HCM (95%), RIT1 → HCM (70%)
• The cortical organoid pathophysiology entry for neurodevelopmental delay is a nice inclusion
• Differential diagnoses appropriately cover the full RASopathy spectrum (CFC, Costello, NF1, NSML)
• The MEK inhibitor (trametinib) treatment entry reflects the frontier of emerging therapy and is responsibly noted as emerging/case-report level

---

Conformance Issues

🔴 Moderate: Evidence source misclassification in datasets section

All three GEO dataset entries use evidence_source: HUMAN_CLINICAL, but two are iPSC/organoid experiments:

• geo:GSE213798 — cortical organoids from NS-iPSCs → should be IN_VITRO (correctly labeled so in the pathophysiology section!)
• geo:GSE131069 — RAF1 S257L/+ iPSC-derived cardiomyocytes → should be IN_VITRO
• geo:GSE188238 — includes both human LV tissue AND iPSC-cardiomyocytes → debatable, but IN_VITRO or split entries would be more accurate

The inconsistency between datasets section (HUMAN_CLINICAL) and pathophysiology section (IN_VITRO) for the same GEO experiments needs to be resolved.

🔴 Moderate: Truncated snippets using ... may fail validate-references

Several snippets abbreviate mid-sentence content with ..., which the reference validator checks as exact substrings. These will likely fail:

Location	Reference	Snippet (truncated)
Classifications	PMID:41675685	"The main reason for referral was diagnostic assessment due to...heart disease (13/24; 54.1%)."
Classifications	PMID:41675685	"RASopathies are a heterogeneous group of conditions of the RAS/mitogen-activated protein kinase pathway..."
MEK Inhibitor Therapy	PMID:41718520	"Trametinib...has been shown to improve NS-HCM outcomes."
Definitions	PMID:41675685	"RASopathies...presenting with overlapping features..."

For MEK Inhibitor Therapy, the full sentence is available in the abstract: "Trametinib, an MEK inhibitor that attenuates abnormal signaling in the RAS/MAPK pathway, has been shown to improve NS-HCM outcomes." — the full version should be used. Fix this →

🟡 Minor: Missing LZTR1 autosomal recessive inheritance

The genetic section correctly notes LZTR1 "can cause autosomal dominant or recessive forms," but the inheritance section only documents Autosomal Dominant. An additional inheritance entry for LZTR1-specific autosomal recessive should be added. Fix this →

🟡 Minor: preferred_term for GO:0001837 is slightly imprecise

# Line 429-432
- preferred_term: endocardial cushion to mesenchymal transition
  term:
    id: GO:0001837
    label: epithelial to mesenchymal transition involved in endocardial cushion formation

The preferred_term implies "cushion cells → mesenchyme" but the actual process is "epithelial-to-mesenchymal transition occurring at the endocardial cushion." A more accurate preferred_term would be "endocardial epithelial-to-mesenchymal transition" or simply match the label.

🟡 Minor: Three treatment entries lack evidence citations

Speech Therapy, Physical Therapy, and Early Intervention Services have no evidence items. Per project guidelines, claims without citable evidence should either include evidence or be moved to notes. For well-established clinical recommendations like these, a review article (e.g., PMID:17222357 mentions these) would suffice. Fix this →

---

Completeness

🔵 Note: Clinical trials pre-fetched but not included

Six clinical trial cache files were modified/added (NCT02157688, NCT02280044, NCT06122870, NCT06307223, NCT06818058, NCT07268534) but the YAML has no clinical_trials section. If these are relevant to Noonan syndrome, they should be added. If pre-fetched for future work, that's fine—just noting the apparent gap.

🔵 Note: PMID:17143285 (SOS1 paper) cited for SHP2 mechanism

The SHP2 Gain-of-Function pathophysiology entry cites PMID:17143285 (Roberts 2007, a SOS1 paper) for the statement about SHP2 enhancement of ERK signaling. The statement is in that paper's background, so it's not wrong, but a dedicated SHP2/PTPN11 reference (e.g., PMID:11992261 Tartaglia 2002) would be stronger primary evidence for that mechanism.

---

Quick Validation Recommended

Before merging, run:

just validate kb/disorders/Noonan_Syndrome.yaml
just validate-references kb/disorders/Noonan_Syndrome.yaml
just validate-terms-file kb/disorders/Noonan_Syndrome.yaml

The truncated snippets issue will likely surface in validate-references.

---

Overall: This is high-quality curation with strong biological grounding, comprehensive ontology coverage, and good use of recent literature. The moderate issues (evidence_source in datasets, truncated snippets) should be fixed before merging; the minor issues can be addressed at discretion.

[claude]

Claude finished @caufieldjh's task in 3m 15s —— View job

---

PR Re-Review: Update Noonan Syndrome

• Analyzing updated PR (commit: "Address review comments")
• Read updated Noonan Syndrome YAML
• Checked all previously flagged issues against the latest commit
• Verified new snippets against reference caches
• Posted updated review

---

Summary

The "Address review comments" commit successfully resolves all five issues raised in the first review. All snippets were verified against cached reference abstracts.

---

Issues from First Review — Status

Issue	Severity	Status
GEO dataset evidence_source misclassification	🔴 Moderate	✅ Fixed
Truncated snippets with ... (4 instances)	🔴 Moderate	✅ Fixed
Missing LZTR1 autosomal recessive inheritance	🟡 Minor	✅ Fixed
preferred_term for GO:0001837 imprecise	🟡 Minor	✅ Fixed
Three treatments lacking evidence	🟡 Minor	✅ Fixed
PMID:17143285 as sole SHP2 evidence	🔵 Note	✅ Addressed

Verification details:

• GSE213798 → IN_VITRO ✅; GSE131069 → IN_VITRO ✅; GSE188238 → split into HUMAN_CLINICAL (LV tissue) + IN_VITRO (iPSC) ✅
• PMID:41718520 MEK snippet: "Trametinib, an MEK inhibitor that attenuates abnormal signaling in the RAS/MAPK pathway, has been shown to improve NS-HCM outcomes." — exact match ✅
• PMID:41675685 snippets (definitions and classifications): both now use full sentences — exact matches ✅
• AR inheritance (PMID:20301303): "NS caused by pathogenic variants in LZTR1 can be inherited in either an autosomal dominant or an autosomal recessive manner." — exact match ✅
• Treatment evidence (PMID:17222357): "Physiotherapy and/or speech therapy should be offered if indicated." — exact match ✅
• Early Intervention (PMID:20301303): "Developmental disabilities are addressed by early intervention programs and individualized education strategies." — exact match ✅
• PMID:11992261 added as dedicated SHP2/PTPN11 reference; snippet "A gain of function was postulated as a mechanism for the disease." — exact match ✅

---

Two Remaining Minor Issues (Pre-existing, Not Previously Flagged)

These were present in the original commit and not caught in the first review pass:

🟡 has_subtypes PTPN11 snippet has trailing ...

At kb/disorders/Noonan_Syndrome.yaml line ~39:

snippet: >-
  Final diagnoses included 15 individuals with Noonan syndrome (nine with
  variants in PTPN11, two in SOS1, and one each in LZTR1, A2ML1, and MRAS...)

The abstract reads "...and MRAS, besides one with variants in both LZTR1 and SOS1)" — the trailing ...) won't match as a substring. Fix: replace with "Final diagnoses included 15 individuals with Noonan syndrome (nine with variants in PTPN11, two in SOS1, and one each in LZTR1, A2ML1, and MRAS, besides one with variants in both LZTR1 and SOS1)". Fix this →

🟡 diagnosis snippet uses ... mid-sentence (PMID:41675685)

Around line ~1106:

snippet: >-
  This retrospective study analyzed...individuals diagnosed with Noonan
  syndrome and related disorders previously submitted to diagnostic molecular
  analysis through next-generation sequencing techniques.

Fix with full abstract text: "This retrospective study analyzed the medical records regarding clinical and molecular data from 2018 to 2024 in a single center for rare diseases of individuals diagnosed with Noonan syndrome and related disorders previously submitted to diagnostic molecular analysis through next-generation sequencing techniques." Fix this →

---

Quick Validation Recommended

just validate kb/disorders/Noonan_Syndrome.yaml
just validate-references kb/disorders/Noonan_Syndrome.yaml
just validate-terms-file kb/disorders/Noonan_Syndrome.yaml

The two remaining ... snippets will likely surface in validate-references.

---

Overall: All moderate and minor issues from the first review have been correctly addressed with exact-match snippets. The two remaining pre-existing ... snippet issues are straightforward fixes. The entry is otherwise well-structured, biologically accurate, and ready to merge after those two snippets are corrected.